Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia

Fig. 2

Mean ADAS-Cog12 score change from baseline at weeks 4, 12, 24, and 36 (observed value). The mean change from baseline to week 36 on the ADAS-Cog12 (with scores ranging from 0 to 75 and higher scores indicating greater impairment) by full analysis set was showed. Error bars represent standard errors (SE). p values are obtained from the Wilcoxon rank sum tests

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193